This review outlines the analgesic role of perineural adjuvants for local anesthetic nerve block injections, and evaluates current knowledge regarding whether adjuvants modulate the neurocytologic properties of local anesthetics.
INTRODUCTION
To date, local anesthetics have typically been the mainstay of regional anesthesia. Adjuvant medications in perineural injections modulate or prolong conduction block, sometimes via mechanisms that have yet to be understood. Clonidine, an a-2 agonist, is known to primarily exert its effects in the central nervous system for blood pressure, and is a well established drug for intrathecal and epidural injection (also primarily via a-2 agonism). Clonidine's a-2 effects also appear to attenuate the development of chronic pain responses [1] . Clonidine and another a-2 agonist, dexmedetomidine, however, exert their perineural analgesic effects via other channel mechanisms unrelated to a-2 mediation [2, 3] . Buprenorphine, an opioid with mixed m-agonist and k-antagonist activity, acts at the systemic level to produce analgesic as well as antihyperalgesic effects, whereas its perineural effects include similarity to local anesthetics in blocking synaptic transmission [4, 5] . Steroids, such as dexamethasone, have systemic antinausea and antinociceptive effects, with possible decreased C-fiber transmission with perineural administration [6] . Midazolam, primarily known as a gamma-aminobutyric acid (GABA) A agonist, may have similar pain modulation effects by acting as an agonist in the periphery via the 18 kDa translocator protein [7 && ], formerly known as the 'peripheral benzodiazepine receptor'.
The use of dexmedetomidine [3, 8, 9] , or combined clonidine-buprenorphine-dexamethasone (C-B-D) [10, 11, 12 && ,13 && ], as adjuvants to local anesthetics in peripheral nerve blocks appears to clinically increase density and duration of blocks and to potentially decrease the total amount of local anesthetic required clinically. Local anesthetics are inherently toxic to neurons through disruption of signal transmission and cell membrane and subcellular proteins. Safety data for local anesthetics combined with the described adjuvants are otherwise not well known. This review entails the mechanisms, specific dosing, and clinical effects of adjuvants to local anesthetic-containing perineural injections.
DEXMEDETOMIDINE
Similar to clonidine, dexmedetomidine exerts its typical clinical effects via agonism at centrally located a-2-adrenergic receptors. Peripherally, however, it may exert its analgesic effects by maintaining hyperpolarization of nerve fibers and blocking synaptic transmission; peripheral addition of a-antagonists were not shown to decrease analgesic effects of dexmedetomidine [3] . Animal [14] and clinical [15, 16] models have shown the safety of intrathecal administration of dexmedetomidine. Prior to a 2008 study [8] , no safety data for perineural use of dexmedetomidine were available. When included in sciatic nerve blocks in rats as an adjuvant to bupivacaine, dexmedetomidine was found to actually decrease perineural inflammation compared with bupivacaine alone [8] . This inhibition of inflammation may be due in part to decreasing the binding activity of nuclear factor kappa B [17 & ]. Subsequent research utilizing this safety data has validated the clinical efficacy of dexmedetomidine [9] . Further studies showing dexmedetomidine in combination with other adjuvants have yet to be performed.
CLONIDINE-BUPRENORPHINE-DEXAMETHASONE
In a 2009 review, Williams et al. [10] discussed the pharmacology of, and the reasons for, employing the combined nerve block adjuvants clonidine, buprenorphine, dexamethasone, and midazolam. The authors note that, in the presence of clonidine, a-2 receptors on macrophages at the site of tissue damage create a shift toward an anti-inflammatory state [1] . Buprenorphine has presumed m-agonism at the site of perineural injection, and may also inhibit voltage-gated sodium channels at the site of perineural injection far more effectively than other opioids [5] . Dexamethasone is also presumed to have peripheral nerve activity, through inhibition of C-fiber transmission, although causing minimal direct peripheral nerve damage compared with hydrocortisone or triamcinolone [18] in clinically relevant doses. Preservatives added to steroids such as benzyl alcohol and propylene glycol have known neurolytic effects, so it is important to avoid steroid adjuvants with any preservatives (preservative-free dexamethasone sodium phosphate is recommended by the authors). Midazolam, acting primarily as a GABA-A agonist, was previously thought to attenuate nerve blockade by acting at peripheral GABA-A receptors [19] , although this more recently has been attributed to translocator protein activation [7 && ]. Although clonidine has been approved by the Food and Drug Administration for intrathecal and epidural uses, its safety for use in peripheral nerve blocks can be categorized as 'grandfathered' and is generally accepted in textbooks of anesthesiology. Buprenorphine has been shown to induce apoptosis in vitro in isolated neuroblastoma-glioma hybrid cells [20] , but at concentrations (100 mmol) higher than in regular clinical use (25 mg/ml). To our knowledge, other than in recent studies [11, 12 && ], preservative-free dexamethasone sodium phosphate for perineural injection has not fully undergone proper safety testing, nor have there been any specific studies examining its coadministration with local anesthetics. Although the safety of midazolam has been examined in intrathecal animal models [21] (1.7-2.5 mg/ml infusions) and human clinical
KEY POINTS
Local anesthetics are by nature neurotoxic; this neurotoxicity is worsened when combined with midazolam. However, there is a reasonable clinical concentration threshold of combined C-B-D that is nontoxic when combined with midazolam (33 mg/ml) and not contributory to worsening baseline neurotoxicity when combined with local anesthetics.
High (supraclinical) concentrations of some adjuvants combined with local anesthetics, or in some cases as single drugs, can be harmful in vitro. studies [22] (2 mg/injection), these generalizations cannot be directly applied to in-vitro dorsal root ganglia [11] (33 mg/ml) or in-vivo rat peripheral nerve models [12 && ] (33 mg/ml) when much lower concentrations are used. Although these perineural adjuvants are commonly used systemically, and somewhat well studied at the neuraxial level, the central theme is the need for further perineural animal model safety testing as dictated by extramural research funding priority, as well as better establishment of the lowest possible effective doses for off-label use [23 & ]. In a 2011 basic science study [11] , several adjuvants were explored regarding the neurocytotoxic effects when combined with ropivacaine. Sensory neurons (dorsal root ganglia) were isolated from rats and bathed in solutions containing various combinations of ropivacaine 0.25%, with or without buprenorphine, clonidine, dexamethasone, or midazolam, or with the four adjuvants alone, for 2 or 24 h. Among many findings, it was noted that the addition of high (supraclinical) concentrations of clonidine and midazolam to ropivacaine increased neuronal death after 2 h. At estimated clinically used concentrations, however, there was no impact of clonidine, buprenorphine, or dexamethasone on the neurotoxicity of ropivacaine. When C-B-D was combined with midazolam (and not ropivacaine) ( Fig. 1) , there was no greater neurotoxicity than that seen after isosmolar choline control treatment. In vitro, dexamethasone at higher concentrations (133 vs. 66.6 mg/ml), as part of C-B-D, did show an incremental neurotoxic effect when added to ropivacaine. Midazolam was found to increase the neurotoxicity of ropivacaine, even at low midazolam concentrations (16.6 mg/ml). There was no in-vitro neuroprotective effect noted with any of these combinations of adjuvant drugs combined with ropivacaine (a drug approved by the Food and Drug Administration for perineural use). In other words, C-B-D combined with ropivacaine showed neuronal cytotoxicity primarily driven by ropivacaine and not by C-B-D (with dexamethasone at 66.6 mg/ml), whereas the combination of clinical concentrations of C-B-D-midazolam showed no difference in neuronal cytotoxicity when compared with isosmolar choline control solution.
To summarize, perineural analgesia that excludes local anesthetics would be potentially 'relatively neuroprotective', but none of these adjuvants at the concentrations studied were absolutely neuroprotective (in vitro) when combined with ropivacaine.
The study [11] was limited (e.g., resources were available to explore in-vitro effects on ropivacaine, but not in combination with other local anesthetics), but establishes data that have broad implications. Medications injected perineurally (in vivo) can diffuse into surrounding tissues, and may be metabolized or absorbed by the surrounding vasculature, potentially lowering neurotoxic effects produced by direct contact. These mitigating factors are not subject to analysis in an in-vitro model. Perineural local anesthetics in clinical scenarios primarily act at the axon of nerves, whereas in this study [11] , the primary sensory neuron (i.e., cell body) was exposed to the drug/combination. Drug concentrations used in portions of this study [11] were commonly well above clinical concentrations, rendering neurons in this model more sensitive to potential neurotoxic effects. Because these drugs were neither metabolized nor absorbed by surrounding vasculature, the neurons were exposed to higher net concentrations of the adjuvants (with or without ropivacaine, specifically in the 24-h exposure experiments). These factors theoretically provide a higher margin for safety, given the lack of neurotoxic findings with C-B-D adjuvants added to ropivacaine, or with C-B-D added to midazolam. The dosing parameters established by this study are clinically relevant, based on doses used in previous clinical studies, and the dose concentrations deemed well tolerated in vitro were used in subsequent in-vivo work. The article [11] emphasizes the need for further investigation, especially regarding time-dependent and concentration-dependent neurotoxicity of combinations of dexamethasone and local anesthetics. The authors also suggest that their findings indicate that midazolam should not be combined with any local anesthetic for perineural injections until further safety data can be gathered.
Advancing beyond the cellular model, a recent 2015 study [12 && ] evaluated the effect of bupivacaine combined with the aforementioned C-B-D adjuvants on rat perineural and dorsal root ganglia tissue. Also evaluated was the chemical compatibility and solubility of such combinations for storage and injection. For the in-vivo peripheral nerve and dorsal root ganglia toxicity study, combinations of saline control vs. bupivacaine-C-B-D or midazolam-C-B-D were injected perineurally (sciatic) in rats. Behavioral observation of all animals was carried out, and after 15 days, neural tissue was harvested and evaluated for dorsal and ventral root fiber degeneration, gliosis, and neuronal vacuolization. The results revealed no behavioral changes with these single injections of any combination of the above drugs at either 1 or 15 days. There were also no major nonreversible motor or proprioceptive differences between the control group and the above adjuvants with bupivacaine ( Fig. 2) . Upon histopathological examination, there were no changes detected in the sciatic nerve, the dorsal or ventral nerve roots, or the dorsal root ganglia. Experiments with multimodal infusions were similarly nontoxic and behaviorally reversible.
In the chemical compatibility portion of the study, the authors employed concentration data from the simultaneous in-vivo investigation. Using these concentrations, chemical compatibility for refrigerated storage of the described combinations was established. The combination of bupivacaine with C-B-D was shown to be stable for single injection. Although this was a small study underwritten by the Department of Defense (as opposed to a major pharmaceutical manufacturer), the results establish strong interval evidence for the safety of these drugs via perineural injection in vivo. Metabolic breakdown of drugs and lower bioavailability was avoided by local injection, enhancing the accuracy of the doses employed. Larger scale animal models and subsequent human testing will be certainly useful, pending extramural funding for such study, to reinforce these findings.
Given the known safety of these medications in vitro and in vivo, their off-label adjuvant use in peripheral nerve blocks has also been described clinically [13 && ]. In a large quality-improvement study from the senior author's institution (B.A.W.), data for various lower and upper extremity perineural single injections were reviewed. The drug combination entailed bupivacaine with C-B-D. Duration of blockade was 37.0 h (interquartile range 30-49 h). The incidence/severity of rebound pain was also reported in the context of adjuvant dose thresholds. The rebound pain results showed that for patients undergoing spinal anesthesia coupled with L2-L4 and L4-S3 nerve/plexus blocks for total knee or hip arthroplasty, there was an increased incidence/severity of rebound pain with lower doses of both perineural buprenorphine (300 mg associated with more rebound pain, vs. >300 mg) and higher doses of dexamethasone (4 mg with more rebound pain vs. 2 mg). Clonidine (perineural dose range 50-100 mg) had no effect on rebound pain with any block method. When examining patients undergoing brachial plexus blocks for upper extremity surgeries, the addition of buprenorphine was also associated with prolonged duration of perineural analgesia. All results are described in Fig. 3 .
The data from this [13 && ] recent qualityimprovement observation study introduce the clinical use of local anesthetics combined with the various adjuvants discussed earlier. The mixture of drugs was injected simultaneously, resulting in nerve blocks of substantial duration (33 h for lumbar plexus and sciatic anesthetic nerve blocks for total knee arthroplasty and for upper extremity blocks). The knee replacement analgesic duration was increased by addition of 2 mg (but not 4 mg) dexamethasone, whereas brachial plexus analgesic duration was extended by the use of buprenorphine at least 200 mg. As the 2 mg total perineural dexamethasone appeared to be clinically sufficient after the described lower extremity blocks, and that higher doses yielded higher associated rebound pain incidence and severity, there appears to be no need to increase perineural dexamethasone doses beyond 2 mg (i.e., 1 mg per blocked nerve/plexus in a dual nerve/plexus block). Buprenorphine dosing was not associated with longer block duration after lower extremity surgery, but doses above 300 mg were associated with less rebound pain. Based on these observations, future work could be directed toward finding an upper limit of dosing based on the aforementioned toxicology and chemical compatibility data. Since this was a retrospective review of quality improvement data, and in the absence of comparisons with local anesthetics sans adjuvants, a randomized control trial is the next appropriate step to fully elucidate the effects of these adjuvant medications.
EFFECTS ON MOTOR BLOCKADE
The degree to which these adjuvants affect motor blockade of local anesthetics, an often undesirable side-effect, is less well defined. Dexmedetomidine and clonidine have both been found to prolong sensory, but also motor blockade, when combined individually with local anesthetics for use in supraclavicular brachial plexus blocks. When compared with one another, addition of dexmedetomidine (as opposed to clonidine) leads to a more pronounced motor blockade [24] . Addition of dexamethasone to 0.25% bupivacaine for brachial plexus blocks has also been shown to significantly increase duration of motor blockade, but a dose-response relationship with increasing concentrations of dexamethasone was not observed [25] . Buprenorphine was not observed to speed the onset of motor blockade in Median rebound pain score  Factors influencing rebound pain score Positive correlation with higher baseline preop movement pain scores, P = 0.002
Median block duration
Positive correlation with 4 mg total perineural dexamethasone dosing (as opposed to 2 mg), P < 0.001
Negative correlation with >300 µg total perineural buprenorphine (as opposed to ≤ 300 µg buprenorphine ), P = 0.018 Summary: higher preop pain with movement predicts a higher associated rebound pain. Using 4 mg perineural dexamethasone (2 mg per plexus) is associated with higher rebound pain scores (vs 1 mg per plexus). Using>300 µg total perineural buprenorphine (e.g., >200 µg buprenorphine per plexus) was associated with lower rebound pain scores (than was ≤150 µg per plexus). If dexamethasone = 2mg (N = 199) Summary narrative interpretation: when perineural buprenorphine >300 µg = (most commonly 300 µg per plexus) and perineural dexamethasone = 2 mg (i.e., exactly 1 mg per plexus), then five patients will have rebound pain less than preop pain score with movement before one patient enjoys similarly low rebound pain using less buprenorphine (≤300 µg perineural total) and more dexamethasone (4mg perineural total) or no dexamethasone.
Block duration constant of lumbar plexus-sciatic blocks: combination with levobupivacaine in interscalene blocks [26] ; these authors were unaware of any trials that had specifically examined changes in motor block duration based on addition of buprenorphine to local anesthetics. No trials exist examining the prolongation of motor block when combining clonidine, buprenorphine, and dexamethasone with local anesthetics. Therefore, it is difficult to determine what effect if any these adjuvants may have on prolonging time to ambulation, effectiveness of physical therapy, or discharge from the hospital. Logic would indicate that when such four-drug multimodal perineural blocks are combined with spinal anesthesia (e.g., for lower extremity joint replacement surgery), there is an effective dose (in 50% [i.e., ED50] or in 95% [i.e., ED95]) wherein a fixed dose of adjuvants will lead to the smallest (higher than zero) duration of motor block, thus creating an optimal ratio of sensory-to-motor block duration. It will be important in future clinical research to emphasize that when the definitive lower extremity anesthetic is being provided by a spinal technique, that a 'zero' motor block duration will most likely jeopardize a meaningful analgesic duration. Instead, the optimal motor block duration would roughly equate the duration of motor block from the residual spinal, and block-specific multimodal sensory analgesia would incorporate true motor-sensory separation for ideally more than 12-24 h after the spinal (and perineural local anesthetic) motor effects have dissipated, such that focused immediate postoperative physical therapy can maximize the remaining perineural analgesia provided by the adjuvants. This dose-finding challenge will likely mark the ultimate research goal for fast-track joint replacement (i.e., same-day or next-day discharge home) as well as for moderately invasive outpatient orthopedic surgery (such as hip arthroscopy or anterior cruciate ligament reconstruction of the knee). Clinicians over the foreseeable future should carefully titrate via a singleinjection technique adequate pain control with minimal (but likely greater than zero) motor blockade in these patients, especially in a busy outpatient or fast-tracking surgical setting. The senior author predicts that combined midazolam-C-B-D may prove to be a worthwhile analgesic block for cases such as hip arthroscopy with minimal procedures beyond debridement (e.g., L2-L4 psoas compartment block with or without an L4-S3 parasacral plexus block), or anterior cruciate ligament reconstruction (e.g., with an L2-L4 femoral block with or without an L4-S3 gluteal/subgluteal sciatic block). We do not forecast that the midazolam-C-B-D combination will be sufficiently potent for major L2-L4 analgesia in arthroplasty or other resurfacing procedures of the hip or knee; it seems more likely that at least a low concentration local anesthetic will be required.
CONCLUSION
This review provides a reasonable foundation for establishing the safety and rational clinical administration and dosing of local anesthetics (e.g., bupivacaine, ropivacaine) combined with the adjuvants clonidine, dexamethasone, and buprenorphine. We now know that midazolam should never be combined with local anesthetics, with basic science studies coming after two clinical studies [27, 28] before in-vitro testing of this combination demonstrating significantly worsened neuronal cytotoxicity. C-B-D in combination was found to be well tolerated at clinical concentrations combined with local anesthetics in vitro and in vivo; midazolam, however, with local anesthetics was not. As these studies were not industry-sponsored, they were relatively small, and further large animal studies and subsequent human trials are still needed (pending extramural funding research priority) before the physiologic analgesic mechanisms and/or neurotoxicity risk of these adjuvant medications is fully understood. Once understood, the subsequent clinical utility and efficacy of these drugs can be optimally utilized in the future, en route toward prolonged analgesia with a singleinjection nerve block in cases wherein perineural catheters may prove to be unnecessary (i.e., when an approximate 36-h analgesic-duration block is reliably available for clinical use).
